or Try an Advanced Search...

    Technical Analysis for SXTP - 60 Degrees Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.26 2.02% 0.01
    SXTP closed up 2.02 percent on Monday, July 1, 2024, on 33 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical SXTP trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 50 DMA Bearish 2.02%
    Expansion Pivot Sell Setup Bearish Swing Setup 2.02%
    Outside Day Range Expansion 2.02%
    Wide Bands Range Expansion 2.02%
    Oversold Stochastic Weakness 2.02%
    50 DMA Support Bullish -3.95%
    Wide Bands Range Expansion -3.95%
    Older End-of-Day Signals for SXTP ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 9 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    Up 1% about 9 hours ago
    60 Minute Opening Range Breakdown about 10 hours ago
    Down 3% about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SXTP Chart by TradingView
    Basic chart:

    Profile

    60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Pharmaceutical Infectious Diseases Infection Malaria Covid 19 Dengue Epidemiology Tropical Diseases Candidiasis Dengue Fever Tick Borne Diseases Treatment Of Infectious Diseases Vaccine Preventable Diseases

    Is SXTP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
    Jun 11 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
    May 30 Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
    May 20 60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
    May 15 60 Degrees Pharmaceuticals reports Q1 results
    May 15 60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
    May 8 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
    May 2 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
    Apr 3 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
    Apr 3 60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
    See more SXTP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.65
    52 Week Low 0.2011
    Average Volume 567,558
    200-Day Moving Average 0.51
    50-Day Moving Average 0.26
    20-Day Moving Average 0.29
    10-Day Moving Average 0.27
    Average True Range 0.03
    RSI (14) 42.53
    ADX 22.33
    +DI 15.84
    -DI 19.72
    Chandelier Exit (Long, 3 ATRs) 0.31
    Chandelier Exit (Short, 3 ATRs) 0.33
    Upper Bollinger Bands 0.35
    Lower Bollinger Band 0.23
    Percent B (%b) 0.23
    BandWidth 41.32
    MACD Line 0.00
    MACD Signal Line 0.00
    MACD Histogram -0.006
    Fundamentals Value
    Market Cap 1.5 Million
    Num Shares 5.8 Million
    EPS -0.59
    Price-to-Earnings (P/E) Ratio -0.44
    Price-to-Sales 28.28
    Price-to-Book 0.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.29
    Resistance 3 (R3) 0.28 0.27 0.28
    Resistance 2 (R2) 0.27 0.26 0.27 0.28
    Resistance 1 (R1) 0.26 0.26 0.27 0.27 0.28
    Pivot Point 0.25 0.25 0.25 0.25 0.25
    Support 1 (S1) 0.25 0.25 0.25 0.25 0.24
    Support 2 (S2) 0.23 0.24 0.23 0.24
    Support 3 (S3) 0.23 0.23 0.23
    Support 4 (S4) 0.23